Compare Cytokinetics Inc (CYTK) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Emerson Electric Co. — how do they compare? Cytokinetics Inc trades at $76.51 (market cap $10.63B), while Emerson Electric Co. trades at $164.49 (market cap $91.69B). The key difference: Emerson Electric Co. is far larger — about 8.6× Cytokinetics Inc's market cap, and Emerson Electric Co. pays a 1.35% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | EMR | |
|---|---|---|
Market Cap | $10.63B | $91.69B |
Sector | Technology | Industrials |
52-Week High | $87.26 | $164.38 |
52-Week Low | $34.31 | $123.30 |
Enterprise Value | $10.74B | $102.77B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Emerson Electric (EMR) trades at $164.56, up 3.7% on the day, reflecting strong momentum after three consecutive quarterly earnings beats. The stock exhibits a bullish technical setup, with key resistance at $168, while fundamentals show solid revenue growth and a 13.83% net income margin. Recent news highlights Q3 2026 results exceeding expectations, driven by 7% organic growth and strategic acquisitions like Glue Inc. to bolster AI capabilities in test and measurement.
Outlook remains positive with raised 2026 guidance, though valuation multiples like a P/E of 35.97 suggest premium pricing. Risks include execution challenges in integrating acquisitions and macroeconomic pressures on industrial demand. Analyst consensus favors Buy ratings with a $171.33 price target, indicating modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
